Annexon, Inc.
Clinical trials sponsored by Annexon, Inc., explained in plain language.
Develops complement-based therapies for autoimmune and neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection aims to stop vision loss in dry AMD patients Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New hope for GBS: Single-Dose drug enters final testing Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Can a targeted antibody calm the immune attack in Huntington's disease?
Disease control CompletedThis phase 2 trial is testing an experimental drug called ANX005 in about 28 people who have Huntington's disease or are at risk of developing it. ANX005 is given as an intravenous infusion and works by blocking a complement protein, C1q, which is part of the immune system and ma…
Phase 2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
Disease control CompletedThis phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…
Phase 2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC